Abstract Details

Title COVID-19 outcomes in hospitalized patients with pre-existing neurodegenerative diseases in Chicagoland area

Topic General Neurology

Presentation(s) S21 - Neuroepidemiology (2:32 PM-2:40 PM)

Poster/Presentation
Number 004

Background COVID-19 outcomes in patients with pre-existing neurodegenerative diseases are not well-described. We hypothesize they may have increased risk of morbidity and mortality due to baseline disability and neurologic dysfunction.

Objective To assess morbidity and mortality of acute COVID-19 infection in hospitalized patients with neurodegenerative diseases and compare with age-matched controls.

Design/Methods Retrospective cohort study using Rush COVID-19 Registry, which includes data from 3 hospitals in Chicagoland area. Adults hospitalized with acute COVID-19 infection within a 3-month period (March to June) were included, and two cohorts were created including a neurodegenerative cohort (ND) identified based on ICD-10 codes (for dementia, Alzheimer’s disease, Parkinson’s disease and others) and control cohort who were 1:1 age-matched with ND subjects. Primary outcomes were death, intubation and ICU admission, which were compared using chi squared test with p<0.05 considered significant. Secondary outcomes included presenting COVID-19 symptoms, length of stay, discharge disposition, oxygen use and development of encephalopathy.

Results

We included 132 ND subjects and 132 controls. Baseline demographic characteristics were similar. There was no difference in mortality (19.7% ND vs 23.5% control, p=0.45) or ICU admission rate (31.5% ND vs 35.9% controls, p=0.43), however intubation or invasive ventilation was more frequent in the control group (11.4% ND vs 23.2% controls, p=0.008). COVID-19 infection was more likely to present as altered mental status in ND subjects, whereas respiratory symptoms were more common amongst controls. ND subjects had higher rates of encephalopathy during the hospitalization and controls received oxygen therapy more frequently. Finally, ND subjects were more commonly discharged to nursing home or hospice, and controls tended to be discharged to acute rehabilitation facility or home.

Conclusions

Hospitalized COVID-19 patients with neurodegenerative diseases had similar mortality rates compared to age-matched controls, but were more likely to develop encephalopathy. Future studies can assess long-term sequelae.

Authors/Disclosures
Roshni A. Patel, MD (Jesse Brown VA) PRESENTER	Dr. Patel has nothing to disclose.
Glenn T. Stebbins, PhD (Rush University Medical Center)	Dr. Stebbins has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Biogen. Dr. Stebbins has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Partners Healthcare System. Dr. Stebbins has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for CHDI. The institution of Dr. Stebbins has received research support from Department of Defense. Dr. Stebbins has received research support from Cleveland Clinic Health Systems. Dr. Stebbins has received personal compensation in the range of $500-$4,999 for serving as a Course Director with MDS.
Brandon Barton, MD, FAAN (Rush University Medical Center)	Dr. Barton has nothing to disclose.